Strategies for overcoming imatinib resistance in chronic myeloid leukemia

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Imatinib revolutionized chronic myeloid leukemia (CML) treatment by targeting the BCR-ABL oncoprotein.
• Some CML patients develop resistance or intolerance to imatinib, necessitating alternative therapies.
• Resistance mechanisms include BCR-ABL mutations and BCR-ABL-independent pathways involving SRC-family kinases.

Purpose of the Study:

• To review emerging therapeutic strategies for CML patients who have failed imatinib therapy.
• To discuss the efficacy and mechanisms of action of newer tyrosine kinase inhibitors (TKIs).

Main Methods:

• Review of clinical data and in vitro studies on dasatinib and nilotinib.
• Analysis of resistance patterns to imatinib and the activity spectrum of new TKIs.
• Comparison of the inhibitory profiles of different TKIs against BCR-ABL and SRC-family kinases.

Main Results:

• Dasatinib, a BCR-ABL and SRC-family kinase inhibitor, is active in all phases of CML and Philadelphia chromosome-positive acute lymphoblastic leukemia.
• Dasatinib demonstrates activity against most imatinib-resistant BCR-ABL mutations.
• Nilotinib, another imatinib analog, shows efficacy but has reduced activity against certain BCR-ABL mutations compared to dasatinib; neither targets T315I mutations.

Conclusions:

• Dasatinib and nilotinib represent significant advancements for imatinib-resistant or -intolerant CML.
• These newer TKIs offer improved therapeutic prospects for CML patients.
• Ongoing research continues to explore novel strategies for managing CML post-imatinib failure.